威替米星对SD大鼠的致畸作用

Teratogenicity of vertilmicin in SD rats

目的探讨威替米星对妊娠期SD大鼠的胚胎毒性和致畸作用。方法采用大鼠标准致畸试验,79只孕SD大鼠随机分为4组,每组19或20只。威替米星3个剂量组分别给予威替米星30.0、15.0、7.5 mg·kg～,阴性对照组给予生理盐水,于妊娠d 6～15尾静脉注射给药,每日1次。妊娠d 20处死孕鼠,检查母体妊娠与胎鼠畸形情况。结果威替米星各剂量组SD大鼠的孕鼠增重、活胎率、死胎率、吸收胎率和活胎身长与阴性对照组相比无显著差异(P>0.05)。威替米星30.0 mg·kg^(-1)组活胎体重、胎盘重量与阴性对照组比较有显著差异(P<0.05),但无明显的剂量-反应关系。各实验组均未观察到胎鼠明显的外观、脏器以及骨骼的畸形。结论威替米星剂量≤30.0 mg·kg^(-1)无明显的母体毒性和致畸作用,也无明显的胚胎毒性和胎儿毒性。

AIM To study the embryotoxicity and teratogenicity of vertilmicin in SD rats during the gestational period. METHODS A standard teratogenicity test was performed to investigate the teratogenicity of vertilmicin. Seventy-nine pregnant SD rats were divided into 4 groups （ n = 19 or 20 for each）, three vertilmicin dosage groups （30.0, 15.0, 7.5 mg·kg^-1） and one negative control group （normal saline）. Vertilmicin or normal saline was given via vena caudalis injection from the 6th to 15th day of gestation. Pregnant rats were killed at 20th day of gestation, and the parents and their fetuses were examined. RESULTS There were no significant differences （P 〉 0.05） in weight gain, live fetus rate, dead fetus rate, absorbed fetus rate, and fetus body length between the vertilmicin dosage groups and the negative control group during gestation. Statistical differences （P 〈 0.05） were found between the vertilmicin 30.0 mg·kg^-1 group and the negative control group in weight of fetus body and placenta, but no obvious dose-response relationship. Vertilmicin did not induce any teratogenic effects on the appearance, viscera, and skeletal of the fetuses in three vertilmicin dosage groups. CONCLUSION Vertilmicin had no maternal toxicity, teratogenicity, embryotoxicity, and fetotoxicity in SD rats when used under the dosage of 30.0 mg·kg^-1.